Insiders Are Selling Johnson & Johnson

| About: Johnson & (JNJ)

There was intensive insider selling in Johnson & Johnson (NYSE:JNJ) in July/August 2008, when the stock was trading above $70. The stock peaked at $72.76 in September 2008, and plunged all the way to $46.25 in March 2009 or 36.4% below the September 2008 peak.

Click to enlarge

Intensive insider selling can be defined by the following three criteria:

  1. The stock was sold by three or more insiders within one month.
  2. The stock was not purchased by any insiders in the month of intensive selling.
  3. At least two sellers decreased their holdings by more than 10%.

There was intensive insider selling in Johnson & Johnson again in July/August this year. This was the first time since November 2011, that Johnson & Johnson saw intensive insider selling. Three different insiders decreased their holdings by more than 10%:

  • Michael Ullmann sold 16,140 shares on August 5, and currently holds 55,427 shares or less than 0.1% of the company. Michael Ullmann is Vice President, General Counsel of Johnson & Johnson and a member of the Executive Committee.
  • Paulus Stoffels sold 45,440 shares on July 25, and currently holds 16,801 shares or less than 0.1% of the company. Paulus Stoffels is the Chief Scientific Officer, Johnson & Johnson, and Worldwide Chairman, Pharmaceuticals.
  • Dominic Caruso sold 30,000 shares on July 18, and currently holds 53,534 shares or less than 0.1% of the company. Dominic Caruso is Vice President, Finance and Chief Financial Officer of Johnson & Johnson.

Here is a table of Johnson & Johnson's insider-trading activity by calendar month.

Month Insider selling / shares Insider buying / shares
August 2013 16,140 0
July 2013 75,440 0
June 2013 0 0
May 2013 4,929 0
April 2013 0 0
March 2013 0 0
February 2013 0 0
January 2013 0 0
Click to enlarge

There have been 96,509 shares sold and there have been zero shares purchased by the insiders this year.


The company reported the second-quarter financial results on July 16, with the following highlights:

Revenue $17.9 billion
Net income $3.8 billion
Cash $25.1 billion
Debt $15.0 billion
Click to enlarge


On July 16 the company increased its earnings guidance for full-year 2013 to $5.40 - $5.47 per share. The company's guidance excludes the impact of special items.


Johnson & Johnson's competitors include Covidien (COV), Novartis AG (NYSE:NVS) and Pfizer (NYSE:PFE). Here is a table comparing these companies.

Market Cap: 259.43B 30.15B 179.69B 207.19B
Employees: 127,600 43,400 131,000 91,500
Qtrly Rev Growth (yoy): 0.09 0.02 0.01 -0.14
Revenue: 69.99B 12.14B 57.96B 56.56B
Gross Margin: 0.69 0.57 0.68 0.81
EBITDA: 22.74B 3.33B 17.10B 24.64B
Operating Margin: 0.27 0.22 0.21 0.32
Net Income: 12.86B 1.90B 9.52B 11.09B
EPS: 4.51 3.77 3.86 3.61
P/E: 20.50 16.92 19.02 8.09
PEG (5 yr expected): 2.71 1.97 3.06 4.06
P/S: 3.75 2.48 3.11 3.65
Click to enlarge
Click to enlarge

Johnson & Johnson has the highest P/S ratio among these four companies. There was also intensive insider selling in Covidien in August this year and there was intensive insider selling in Pfizer in May this year.


There have been three different insiders selling Johnson & Johnson and there have not been any insiders buying Johnson & Johnson during the past 30 days. All three of these insiders decreased their holdings by more than 10%. Johnson & Johnson has an insider ownership of 0.02%. The stock is trading at a P/E ratio of 20.50 and a forward P/E ratio of 15.87. Johnson & Johnson has a book value of $24.79 per share. Before entering short Johnson & Johnson, I would like to get a bearish confirmation from the Point and Figure chart. The two main reasons for the proposed short entry are the relatively high P/S ratio and the intensive insider selling activity.

Click to enlarge

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.